Lesson Plan

The Elixir

1889 to 1971, Paris, Vienna, Riviera, Vatican, Montreux • Bryan Johnson's $2M/yr Blueprint protocol (April 2026 routine: 4h46m, rapamycin dropped, lithium and NDGA added); Altos Labs 2025 mesenchymal-drift Cell paper; Loyal LOY-002 senior-dog drug at FDA, first lifespan drug in any species. • May 14, 2026

Before using this lesson plan: Read the full story or listen to the 5-minute narration (works as a bell-ringer).

Quick Use (jump to the section you need)

Discussion questions Extension activities

Lesson Plan: The Elixir

Subject area

STEM with history of medicine: endocrinology, ageing biology, clinical trial design, philosophy of science, and the relationship between popular and laboratory science.

Recommended audience

High-school biology / health science (Years 11-13 / Grades 10-12)

First-year undergraduate biology, biochemistry, medicine, public health

General STEM enrichment for ages 14+

Lesson length

60-75 minutes (one period plus optional follow-up).

Learning objectives

By the end of the lesson, students will be able to:

Describe Charles-Édouard Brown-Séquard's 1 June 1889 lecture at the Société de Biologie and explain why the procedure he reported almost certainly produced its effects through the placebo response rather than through testosterone replacement.

Define the placebo effect and identify why nineteenth-century medicine did not have the conceptual or experimental tools to distinguish it from a real pharmacological effect.

Outline the timeline of testosterone biochemistry from Brown-Séquard's 1889 lecture to the actual isolation of testosterone in 1935.

Describe the subsequent rejuvenation industries of the early twentieth century: Voronoff's xenotransplantation grafts, Steinach's unilateral vasectomy, Niehans's fresh-cell therapy.

Articulate the difference between modern self-experimentation in the longevity field (Bryan Johnson's Blueprint protocol) and the regulated clinical-trial pipeline (Altos Labs' partial-reprogramming work, Loyal's LOY-002 senior-dog drug).

Explain what biological age, DNA-methylation clocks, and Yamanaka factors are, and how the modern field is attempting to convert ageing into a measurable target.

Key terms

Placebo effect, blinded trial, randomised controlled trial

Endocrinology, hormone, gonad, testosterone

Organotherapy, xenotransplantation, allograft, autograft

Vasectomy, vas deferens, Steinach operation

Fresh-cell therapy, cellular reprogramming, Yamanaka factors (Oct4, Sox2, Klf4, c-Myc)

DNA methylation, epigenetic clock, biological age

Mesenchymal drift, partial reprogramming

Senior-dog clinical trial, Expanded Conditional Approval (XCA), pivotal efficacy trial

Animal model, target animal safety

Discovery-class biotech, principal investigator

Pre-class preparation

A periodic table and a basic chemistry of steroid hormones (testosterone, cortisol, oestradiol).

A printed diagram of the male reproductive system showing the vas deferens.

A printed timeline 1850-2030 with major milestones blank for students to fill in.

A short reading: the abstract of the 1889 Brown-Séquard paper (translated) and the abstract of the most recent Altos Labs publication on mesenchymal drift.

Lesson outline

1. Hook (5 min): a distinguished old man and a syringe

Describe the cold open. A seventy-two-year-old professor at the Collège de France, holding three of Europe's most distinguished medical chairs, stands at the Société de Biologie on 1 June 1889 and announces that he has injected himself ten times with crushed-testicle juice and reports that his strength is restored. Ask the class: would you believe him? Why or why not? What evidence would you ask for?

2. Brown-Séquard's experiment in the context of nineteenth-century medicine (10 min)

Brown-Séquard's actual scientific stature: discovered the spinal-cord syndrome that bears his name; founded Archives de Physiologie; Fellow of the Royal Society; succeeded Claude Bernard at the Collège de France.

The extract: water + blood from testicular veins + semen + crushed testicle juice from dogs and guinea-pigs, ten subcutaneous injections over three weeks.

The reported effects: physical strength, mental performance, appetite, relieved constipation, lengthened arc of urine.

The actual biology: the extract was too dilute and too contaminated to deliver meaningful testosterone, and testosterone itself was not isolated as a discrete molecule until 1935 (David, Dingemanse, Freud, Laqueur in Amsterdam). The effects almost certainly came from the placebo response and observer bias.

Discussion: why was the medical community willing to administer this within weeks? (Authority of the source, plausibility of the mechanism, no concept of randomised double-blind trial design, no understanding of the placebo effect as a discrete phenomenon.)

3. The placebo effect as a scientific concept (10 min)

The word "placebo" enters medical English in the eighteenth century but is not formally studied until Henry Beecher's 1955 paper "The Powerful Placebo" in JAMA.

The randomised controlled trial as we know it dates to the 1948 Medical Research Council streptomycin trial.

Brown-Séquard ran the largest natural experiment on the placebo effect that medicine had ever conducted (12,000 physicians, hundreds of thousands of patients) without recognising it as such.

Discussion: when you read a modern self-experiment in longevity (Bryan Johnson's Blueprint), what controls would you look for? What does a single-subject open-label trial tell you, and what does it not tell you?

4. The 20th-century rejuvenation industries (10 min)

Voronoff (1920-1930s): xenotransplantation of chimpanzee testicular tissue slices onto wealthy clients' testicles. By the early 1930s over 500 procedures performed in France. The grafts were rejected immediately and replaced by scar tissue.

Steinach (1920s-30s): unilateral vasectomy as rejuvenation. "To be Steinached" entered the vernacular. W. B. Yeats was Steinached at 69 in Harley Street on 6 April 1934 and attributed his late lyric burst to the procedure. Modern endocrinology: vasectomy does not raise testosterone.

Niehans (1953-1971): fresh-cell therapy with sheep foetal cells. Pope Pius XII, Konrad Adenauer, Winston Churchill, Charlie Chaplin, the Duke of Windsor among reported recipients. No biological mechanism, immediate immune rejection.

Common feature: high-status patient, plausible-sounding mechanism, no controls, profitable.

5. Modern self-experimentation: Bryan Johnson and Blueprint (10 min)

Bryan Johnson, 48, former technology executive in Venice, California.

Blueprint protocol: 4 hours 46 minutes daily routine, over $2 million per year, more than 100 supplements at peak.

April 2026 changes: dropped rapamycin (side effects), added low-dose lithium and NDGA, reduced NMN intake.

Reports biological age more than 5 years younger using DNA-methylation clocks.

November 2025 Blueprint raised $60 million, investors including Kim Kardashian and Paris Hilton.

Critical reading: what is the same as Brown-Séquard? (Wealthy distinguished man, self-experimentation, public reporting of effects, no control group.) What is different? (Modern measurement instruments did not exist in 1889; DNA methylation clocks are real measurements; some of the underlying biology has support.)

6. The legitimate science: Altos Labs and partial reprogramming (10 min)

Altos Labs founded 2022 in San Diego and Cambridge, $3-4 billion in backing including Jeff Bezos and Yuri Milner.

Yamanaka factors (Oct4, Sox2, Klf4, c-Myc): four transcription factors that can revert mature cells to pluripotent stem cells (Yamanaka and Takahashi, 2006). Won the 2012 Nobel Prize.

Partial reprogramming: a brief pulse of Yamanaka factors that resets epigenetic age without dedifferentiating the cell.

Belmonte group's 2025 Cell paper on mesenchymal drift: a pervasive cellular signature of ageing across 40 human tissue types, partly reversed by Yamanaka pulsing.

Barcelona kidney-transplant collaboration: aged donor kidneys perfused with a Yamanaka pulse before transplantation into mice showed significant survival benefit.

Discussion: this is the legitimate science Brown-Séquard was reaching toward without the tools to reach.

7. Loyal and LOY-002: the first FDA-approved lifespan drug? (5 min)

Loyal, founded six years ago by Celine Halioua in San Francisco.

LOY-002 is a senior-dog longevity pill targeting metabolic drivers of ageing.

STAY pivotal efficacy trial: 1,300 dogs across 70 veterinary clinics, completed enrollment July 2025.

FDA accepted the Target Animal Safety section January 2026. Reasonable Expectation of Effectiveness accepted February 2025.

Expanded Conditional Approval filing planned for 2026.

If approved, the first drug approved by any regulator for lifespan extension in any species.

8. Wrap and assignment (5 min)

Pose: "Brown-Séquard reported subjective effects after a 10-injection self-experiment with no controls. Bryan Johnson reports subjective effects after a 5-year self-experiment with no controls. What if anything is different about the two reports as evidence?"

Optional homework: write a 500-word memo arguing for OR against the proposition that Bryan Johnson's Blueprint protocol counts as scientific evidence of slowing ageing. Use specific terms from the lesson (placebo, blinding, controls, biological age, methylation).

Discussion questions

The Brown-Séquard elixir was administered by 12,000 physicians within six months, and patients reported feeling better. Without modern statistical tools, how could anyone have known whether the effect was real? What kind of study design would have settled the question?

The placebo effect is sometimes described as "not a real effect." Argue both sides of this claim. Is the placebo response a measurement artefact, or a real biological phenomenon that is simply not caused by the active compound under test?

Voronoff's monkey gland grafts and Steinach's vasectomies were widely accepted in the medical community of the 1920s. What does this tell you about the relationship between credentialed authority and scientific truth? How is the modern peer-review system intended to reduce that gap?

Compare the evidence base for the Brown-Séquard elixir in 1889, the Niehans fresh-cell therapy in 1953, and the LOY-002 trial in 2026. What has changed about the standards of evidence required to bring a longevity product to market?

Bryan Johnson reports a biological age more than five years younger than his chronological age using DNA-methylation clocks. What does that measurement actually tell you, and what does it not tell you? Is there any way to know whether his protocol is the cause?

Suppose the LOY-002 dog trial succeeds and Loyal becomes the first regulator-approved lifespan-extension drug for any species. Should that change how regulators think about the human equivalent? What would have to be true for the human case to follow?

Extension activities

Calculation: the Brown-Séquard extract was prepared from a dog or guinea-pig testicle and a few millilitres of water. Look up the approximate testosterone content of a mature canine testis (roughly 0.5-1 microgram per gram of tissue), and calculate what a 1 mL subcutaneous injection of crushed-testicle suspension could plausibly deliver. Compare this to the daily endogenous testosterone production of a healthy 72-year-old man (roughly 3-5 mg per day). How many injections would have been needed to make a measurable difference?

Reading exercise: read the abstract of Beecher's 1955 paper "The Powerful Placebo" (JAMA 159:1602) and the most recent published trial of an SSRI antidepressant. Identify in each the role of the placebo arm and the magnitude of the placebo response. Why has the SSRI/placebo gap narrowed in recent decades?

Writing assignment: write a 1000-word essay on the conceptual difference between organotherapy in 1889 and partial cellular reprogramming in 2026. Use the same case study (Brown-Séquard) as the historical anchor and the Belmonte group's 2025 Cell paper as the modern anchor.

Critical reading: find Bryan Johnson's protocol page online and read the most recent change-log entry (rapamycin was removed in 2026). Compare the language he uses to describe the change with the language used in the methods section of a peer-reviewed clinical trial paper. List five linguistic differences.

Time Rhymes